Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In-FI: Fiasp vs Novolog in Hospitalized T2DM
NCT04460326Phase 3Completed
- Sponsor
- Boston Medical Center
- Start
- Dec 2020
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human insulin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boston Medical Center. Primary endpoint: Postprandial Glucose Control at 3 days. Started Dec 2020; status: completed.
02
Drugs
human insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04460326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04460326.